Adverse Effects of Criminal Legal System Involvement: a Qualitative Study Examining the Role of Incarceration and Reentry on Substance Use Trajectories Among Women with Opioid Use Disorders

Overview

Journal BMC Glob Public Health

Specialty Public Health

Date 2024 Dec 16

PMID 39681943

Authors

Sienna Strong-Jones

Kristina Brant

Derek Kreager

Eric Harrison

Abenaa Jones

Affiliations

Soon will be listed here.

Abstract

Background: Women with substance use disorders (SUDs) often experience adversity related to incarceration and reentry that can impact their substance use outcomes. This study aims to examine the adverse effects of incarceration and reentry on substance use outcomes among women with a history of opioid use disorder (OUD).

Methods: We carried out 42 semi-structured interviews (May-July 2022) with women with a history of criminal legal involvement and OUD (n = 20), criminal legal professionals (n = 10), and SUD treatment professionals (n = 12). The interviews focused on women's substance use trajectories, barriers to treatment, and the intersection of the criminal legal system and treatment. None of the women were presently incarcerated during their interviews.

Results: Participants expressed the severe adverse impact of criminal legal involvement on women with OUD. Many women felt traumatized by experiencing detox while incarcerated, especially as they received minimal aid for withdrawal symptoms. Women seeking recovery while incarcerated felt unsupported, being afforded few treatment options, and experiencing stigma. Reentering society after incarceration also posed significant challenges to women's individual recovery goals. Reentry-related challenges such as returning to unsupportive environments, facing difficulties finding employment, lacking secure housing, and facing the stigma of incarceration triggered adverse outcomes, such as relapse among those who were seeking to avoid illicit substances.

Conclusions: Findings suggest a need to evaluate detox protocols, medication for opioid use disorder (MOUD) access, and stigma in the criminal legal system. Interventions facilitating women's reentry, reducing the combined stigma of incarceration and OUD, and restoring agency for women with OUD are also needed.

References

Krinsky C, Lathrop S, Brown P, Nolte K . Drugs, detention, and death: a study of the mortality of recently released prisoners. Am J Forensic Med Pathol. 2009; 30(1):6-9. DOI: 10.1097/PAF.0b013e3181873784. View

U S Department Of Health And Human Services . Opioid abuse in the United States and Department of Health and Human Services actions to address opioid-drug-related overdoses and deaths. J Pain Palliat Care Pharmacother. 2015; 29(2):133-9. DOI: 10.3109/15360288.2015.1037530. View

Binswanger I, Stern M, Deyo R, Heagerty P, Cheadle A, Elmore J . Release from prison--a high risk of death for former inmates. N Engl J Med. 2007; 356(2):157-65. PMC: 2836121. DOI: 10.1056/NEJMsa064115. View

Rich J, McKenzie M, Larney S, Wong J, Tran L, Clarke J . Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015; 386(9991):350-9. PMC: 4522212. DOI: 10.1016/S0140-6736(14)62338-2. View

Waddell E, Baker R, Hartung D, Hildebran C, Nguyen T, Collins D . Reducing overdose after release from incarceration (ROAR): study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. Health Justice. 2020; 8(1):18. PMC: 7349469. DOI: 10.1186/s40352-020-00113-7. View

Ciccarone D, Ondocsin J, Mars S . Heroin uncertainties: Exploring users' perceptions of fentanyl-adulterated and -substituted 'heroin'. Int J Drug Policy. 2017; 46:146-155. PMC: 5577861. DOI: 10.1016/j.drugpo.2017.06.004. View

Tong A, Sainsbury P, Craig J . Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007; 19(6):349-57. DOI: 10.1093/intqhc/mzm042. View

Rhodes Fortino B, Carda-Auten J, DiRosa E, Rosen D . Provision of health care services related to substance use disorder in southern U.S. jails. J Subst Use Addict Treat. 2023; 158:209234. PMC: 10947909. DOI: 10.1016/j.josat.2023.209234. View

Sufrin C, Kramer C, Terplan M, Fiscella K, Olson S, Voegtline K . Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails. JAMA Netw Open. 2022; 5(1):e2144369. PMC: 8777564. DOI: 10.1001/jamanetworkopen.2021.44369. View

10.

Milloy M, Wood E . Withdrawal from methadone in US prisons: cruel and unusual?. Lancet. 2015; 386(9991):316-8. DOI: 10.1016/S0140-6736(15)60073-3. View

11.

Teasdale B, Daigle L, Hawk S, Daquin J . Violent Victimization in the Prison Context: An Examination of the Gendered Contexts of Prison. Int J Offender Ther Comp Criminol. 2015; 60(9):995-1015. DOI: 10.1177/0306624X15572351. View

12.

Green T, Gilbert M . Counterfeit Medications and Fentanyl. JAMA Intern Med. 2016; 176(10):1555-1557. DOI: 10.1001/jamainternmed.2016.4310. View

13.

Beletsky L, Davis C . Today's fentanyl crisis: Prohibition's Iron Law, revisited. Int J Drug Policy. 2017; 46:156-159. DOI: 10.1016/j.drugpo.2017.05.050. View

14.

Benck K, Seide K, Jones A, Omori M, Brinkley Rubinstein L, Beckwith C . United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder. Drug Alcohol Depend. 2023; 247:109863. PMC: 10198943. DOI: 10.1016/j.drugalcdep.2023.109863. View

15.

Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B . Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. PLoS Med. 2020; 16(12):e1003002. PMC: 6938347. DOI: 10.1371/journal.pmed.1003002. View

16.

ODonnell J, Halpin J, Mattson C, Goldberger B, Gladden R . Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016. MMWR Morb Mortal Wkly Rep. 2017; 66(43):1197-1202. PMC: 5689219. DOI: 10.15585/mmwr.mm6643e1. View

17.

Rodriguez M, Colgan D, Leyde S, Pike K, Merrill J, Price C . Trauma exposure across the lifespan among individuals engaged in treatment with medication for opioid use disorder: differences by gender, PTSD status, and chronic pain. Subst Abuse Treat Prev Policy. 2024; 19(1):25. PMC: 11067259. DOI: 10.1186/s13011-024-00608-8. View

18.

Lake S, Hayashi K, Milloy M, Wood E, Dong H, Montaner J . Associations between childhood trauma and non-fatal overdose among people who inject drugs. Addict Behav. 2015; 43:83-8. PMC: 4304975. DOI: 10.1016/j.addbeh.2014.12.014. View

19.

Wakeman S, Rich J . Barriers to Medications for Addiction Treatment: How Stigma Kills. Subst Use Misuse. 2017; 53(2):330-333. DOI: 10.1080/10826084.2017.1363238. View

20.

Martins S, Keyes K, Storr C, Zhu H, Chilcoat H . Pathways between nonmedical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2009; 103(1-2):16-24. PMC: 2699563. DOI: 10.1016/j.drugalcdep.2009.01.019. View